Innovating Works

OPTOGENERAPY

Financiado
Optogenetic Protein Therapy for Multiple Sclerosis
Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously... Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß. Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs. It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness. The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science. In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands. BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness. ver más
31/01/2020
EURECAT
6M€
Duración del proyecto: 38 meses Fecha Inicio: 2016-11-23
Fecha Fin: 2020-01-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-01-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
NMBP-09-2016: Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System
Cerrada hace 8 años
Presupuesto El presupuesto total del proyecto asciende a 6M€
Líder del proyecto
FUNDACIO EURECAT El impulso de la innovación en general y de i + d, en todos los sectores de actividad el impulso de la investigación industrial y el desarro...
Perfil tecnológico TRL 2-3 58M